The Filing Desk

Hinge Health

HNGE · NYSE · Health Care · Financials, fiscal 2023 to 2025

HNGE · Last close · November 13, 2026
$115.39
Value Hinge Health yourself

Hinge Health's revenue rose 50.6% to $588 million in fiscal 2025. Its operating margin was −92.9%, down from −8.2% a year earlier. Free cash flow was $171 million, up 256.0%. It paid out $65 million in dividends and buybacks, 38% of free cash flow. The diluted share count rose 302.5%.

Hinge Health, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 3, 2026 · 0001628280-26-013808 Updated
Revenue
$588M
50.6%
Operating margin
−92.9%
84.8 pts
Net income
−$528M
 
Free cash flow
$171M
256.0%
Return on equity
—
 
Market cap
$10.0B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

What Hinge Health does

Hinge Health sells a digital program for muscle and joint (MSK) care, covering injuries, chronic pain and recovery after surgery. Members use motion-tracking software and a wearable device that gives electrical nerve stimulation, and a care team of licensed physical therapists, physicians and health coaches, supported by AI, monitors the program.

Its customers are mainly self-insured employers, including public-sector employers such as city governments and labor unions. It also serves health plans' fully insured and Medicare Advantage members, and federal insurance plans. It sells through its own sales force and through partners such as health plans and benefit managers.

Hinge Health is usually the only digital MSK provider offered to a client's covered people, and its average contract term was three years at the end of 2025. It earns recurring revenue for the life of each contract, and it aims to reduce its clients' costs. It has a limited operating history.

Its biggest risks, as it describes them

  • It may not carry out its growth plans and strategies.
  • Clients may not renew their contracts, or may renew on worse terms.
  • It may fail to keep existing members or add new ones.
  • It pays upfront costs for each client and partner and may not recover them if relationships don't grow.
  • Competitors and other advances in treating joint and muscle conditions could limit its acceptance.
From Hinge Health's annual report on Form 10-K, filed March 3, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Hinge Health lost money in fiscal 2025: a net loss of $528 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY23FY24FY25
Cash and short-term investments235467364
Debt incl. finance leases———
Net debt (negative means net cash)———
Net debt to EBITDA———
Debt to equity———
Interest coverage———
Current ratio—2.3x1.5x
Quick ratio—2.3x1.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Hinge Health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Hinge Health says to expect

  • Fourth quarter 2026: revenueWe expect revenue to be between $249 million and $251 million, reflecting year-over-year growth of 46% at the midpoint.
  • Full year 2026: revenueWe are raising our revenue guidance to be between $879 million and $881 million, reflecting year-over-year growth of 50% at the midpoint.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 2, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Hinge Health shares on the open market, and 10 insiders sold $546.0 million, $437.5 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 11, 2026Gabriel M.I. MecklenburgDirectorSold plan200,000$122.41$24.5 millionForm 4
Nov 10, 2026James BudgeChief Financial OfficerSold plan35,907$121.62$4.4 millionForm 4
Sep 21, 2026James PursleyPresidentSold plan33,000$94.13$3.1 millionForm 4
Sep 14, 2026Gabriel M.I. MecklenburgDirectorSold plan150,000$93.22$14.0 millionForm 4
Sep 11, 2026Gabriel M.I. MecklenburgDirectorSold plan250,000$88.97$22.2 millionForm 4
Sep 10, 2026Daniel Antonio PerezCEO & Co-Founder, Director, 10% ownerSold plan250,000$89.45$22.4 millionForm 4
Sep 10, 2026James BudgeChief Financial OfficerSold plan55,561$89.45$5.0 millionForm 4
Aug 21, 2026James PursleyPresidentSold plan33,000$88.05$2.9 millionForm 4
Aug 20, 2026Kristina M LeslieDirectorSold1,200$88.23$105,876Form 4
Jul 9, 2026Insight Venture Associates X L.P.10% ownerSold plan181,499$90.20$16.4 millionForm 4
Jul 7, 2026Insight Venture Associates X L.P.10% ownerSold plan244,672$90.23$22.1 millionForm 4
Jul 1, 2026Gabriel M.I. MecklenburgDirectorSold plan83,334$85.05$7.1 millionForm 4
The latest 12 of 50 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25
Piotroski F-score——
Rule of 4045.6%79.6%
Altman Z''−1.37−7.51
Accruals ratio—−98.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25
Net income is positive—Fail
Cash from operations is positivePassPass
Return on assets rose——
Cash from operations exceeds net incomePassPass
Debt fell relative to assets——
Current ratio rose—Fail
Share count didn't riseFailFail
Gross margin rosePassPass
Revenue rose relative to assets——
F-score——
Companies that report no gross profit are scored on the other eight.

Compare

Put Hinge Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Hinge HealthFY2550.6%−92.9%29.0%———
DoximityFY2613.1%33.3%50.6%91.3%−3.3x4Compare
PhreesiaFY2614.5%−1.4%14.1%−2.2%−2.6x6Compare
CertaraFY258.8%5.0%22.6%0.9%1.1x5Compare
WaystarFY2516.5%22.7%25.8%3.5%3.6x5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

3 years of figures

Fiscal yearFY23FY24FY25
Income statement
Revenue293390588
Revenue growth—33.4%50.6%
Gross profit194300468
Research and development110101368
Operating income−130−32−546
Net income−108−12−528
Diluted EPS (US$)−8.31−0.88−7.77
Diluted shares (millions)131455
Cash flow
Cash from operations−6449171
Capital expenditure211
Free cash flow−6648171
Dividends paid000
Share buybacks0065
Acquisitions004
Stock-based compensation21643
Balance sheet at fiscal year end
Cash and short-term investments235467364
Debt incl. finance leases———
Total assets—673745
Total liabilities—257366
Shareholders' equity−424−435179
Margins and ratios
Gross margin66.3%76.8%79.7%
Operating margin−44.6%−8.2%−92.9%
Net margin−36.9%−3.1%−89.9%
Free cash flow margin−22.5%12.3%29.0%
Rule of 40 (growth + FCF margin)—45.6%79.6%
Return on capital———
Return on equity———
Return on assets——−74.5%
Net debt to EBITDA———
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Hinge Health's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Hinge Health.